drugset / Trial / NCT03007823
High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma
Phase 1/2
Completed
20 enrolled
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of melanoma.
Timeline
- Start
- 2016-12-01
- Primary completion
- 2017-12-01
- Completion
- 2019-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | High-activity natural killer | Cell therapy | — | Intravenous |